PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.03), $0.97 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $118.4 million versus the consensus estimate of $112.21 million.

"I am very pleased by the rapid progress that we have made this quarter with the approval and strong U.S. launch of Evrysdi™ for spinal muscular atrophy and the continued growth across our global Duchenne muscular dystrophy franchise," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "We have also made significant advances across our clinical pipeline with a registration-directed trial in mitochondrial epilepsy initiated this quarter and an additional registration-directed trial in Friedreich ataxia to initiate before year end. The mission at PTC has always been to bring therapies to patients with high unmet medical need through investment in innovative technologies and we believe we are well positioned to bring long-term value for all of our stakeholders."

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.